Today: 30 April 2026
Klaviyo stock drops nearly 10% to start 2026 as yields rise — what investors watch next
4 January 2026
1 min read

Klaviyo stock drops nearly 10% to start 2026 as yields rise — what investors watch next

NEW YORK, January 4, 2026, 10:48 ET — Market closed

  • Klaviyo shares fell 9.7% on Friday, sliding with high-growth software as Treasury yields firmed.
  • Peers HubSpot, Braze and Salesforce also dropped, while a broad software ETF underperformed.
  • Focus shifts to U.S. jobs data this week and Klaviyo’s next earnings timing.

Klaviyo, Inc. (KVYO) shares ended the first trading day of 2026 down 9.7% on Friday at $29.32. The stock traded between $32.46 and $29.15 and saw about 4.9 million shares change hands.

The move matters because Klaviyo sits in the high-growth software bucket, where valuations often swing with changes in interest-rate expectations. When bond yields rise, investors tend to pay less for profits that are expected further out.

With U.S. markets closed on Sunday, attention turns to whether Friday’s slide was a one-day reset or the start of a broader rotation out of rate-sensitive growth names. Traders will also look for catalysts that can reprice the Fed outlook before the next round of company earnings.

On Friday, U.S. Treasury yields moved higher and value stocks outperformed growth as markets opened the year, Reuters reported. “Value is outperforming growth,” said Jed Ellerbroek, a portfolio manager at Argent Capital in St. Louis. Reuters

The weakness was not confined to Klaviyo. HubSpot fell 4.7%, Braze slid 5.1% and Salesforce dropped 4.3%, while the iShares Expanded Tech-Software Sector ETF — a basket of software shares that trades like a stock — fell 2.9%.

Zacks Investment Research on Jan. 3 assigned Klaviyo its top “Rank 1 (Strong Buy)” rating and cited upward estimate revisions over the past 60 days. The report listed Klaviyo’s 52-week range at $23.44 to $49.55, putting the shares about 41% below the past year’s high.

Klaviyo sells software that helps consumer brands automate marketing messages across email, text messages and push notifications — prompts sent to phones or browsers. Investors tend to treat the stock as a read-through on digital marketing budgets at e-commerce-focused companies.

For the company, the next test is whether revenue growth holds up after the holiday season while management keeps a close watch on profitability. Customer retention and the cost to acquire new customers will likely stay front and center in the next update.

But the downside scenario is straightforward: if yields keep moving higher on firm economic data, investors can continue to cut exposure to smaller growth software regardless of company execution. A conservative outlook from management, when it reports, would add to that pressure.

Competition remains another watchpoint. Larger platforms and specialist customer-engagement vendors — including Salesforce, HubSpot and Braze — can pressure pricing and raise customer churn risk in a softer demand environment.

Macro catalysts come quickly. Investors will parse the U.S. jobs report due Jan. 9 and the consumer price index on Jan. 13 for clues on whether the Fed has room to keep cutting rates, Reuters reported.

Stock Market Today

  • Biogen Shares Rise 6% After Q1 Earnings Beat Despite Guidance Cut
    April 29, 2026, 9:29 PM EDT. Biogen (NASDAQ: BIIB) shares rose 6% on Wednesday following its first-quarter 2026 earnings report. The biotech posted $2.48 billion in revenue, surpassing analyst expectations of $2.25 billion. Net income, excluding accounting standards (GAAP), increased 19% to over $529 million, or $3.57 per share, above forecasts of $2.95. Growth was driven by strong sales of Leqembi, for early Alzheimer's, up 74%, and the FDA-approved Skyclarys for Friedreich's ataxia. However, Biogen cut full-year adjusted net income guidance by $1 per share citing research and development charges. Revenue is expected to decline mid-single digits from 2025, excluding a pending $5.6 billion acquisition of Apellis Pharmaceuticals. Biogen's strategic shift towards high-potential therapies is underway despite cautious outlook.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Eli Lilly stock ends higher to start 2026 as traders eye JPM conference, earnings
Previous Story

Eli Lilly stock ends higher to start 2026 as traders eye JPM conference, earnings

Global stock markets brace for Venezuela shock as oil weakness and U.S. jobs report loom
Next Story

Global stock markets brace for Venezuela shock as oil weakness and U.S. jobs report loom

Go toTop